$930,000.00 in Sales Expected for AcelRx Pharmaceuticals Inc (ACRX) This Quarter

Equities analysts forecast that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will announce $930,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $550,000.00 and the highest estimate coming in at $1.30 million. AcelRx Pharmaceuticals posted sales of $2.66 million during the same quarter last year, which would indicate a negative year over year growth rate of 65%. The business is expected to report its next earnings report on Tuesday, August 7th.

On average, analysts expect that AcelRx Pharmaceuticals will report full year sales of $6.35 million for the current financial year, with estimates ranging from $1.99 million to $10.70 million. For the next year, analysts forecast that the business will post sales of $23.07 million per share, with estimates ranging from $17.40 million to $28.74 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. The business had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.78 million.



A number of research analysts have commented on ACRX shares. Cantor Fitzgerald started coverage on shares of AcelRx Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $6.00 price target on the stock. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Tuesday, May 15th. Finally, ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $5.11.

NASDAQ ACRX traded up $0.23 on Monday, reaching $4.13. 994,112 shares of the company’s stock traded hands, compared to its average volume of 503,621. AcelRx Pharmaceuticals has a 12 month low of $1.55 and a 12 month high of $5.75. The company has a debt-to-equity ratio of -0.20, a current ratio of 4.05 and a quick ratio of 4.00. The stock has a market capitalization of $187.32 million, a P/E ratio of -3.75 and a beta of 2.36.

Institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP bought a new position in shares of AcelRx Pharmaceuticals in the first quarter worth approximately $113,000. Virtu Financial LLC bought a new position in shares of AcelRx Pharmaceuticals in the fourth quarter worth approximately $120,000. Northern Trust Corp grew its holdings in shares of AcelRx Pharmaceuticals by 60.8% in the first quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock worth $192,000 after purchasing an additional 34,584 shares during the last quarter. Finally, Geller Family Office Services LLC grew its holdings in shares of AcelRx Pharmaceuticals by 175.0% in the fourth quarter. Geller Family Office Services LLC now owns 275,000 shares of the specialty pharmaceutical company’s stock worth $557,000 after purchasing an additional 175,000 shares during the last quarter. Hedge funds and other institutional investors own 8.40% of the company’s stock.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply